Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Trametinib: A Possible New Treatment for Severe Kaposiform Lymphangiomatosis

Trametinib offers new hope in patients battling kaposiform lymphangiomatosis.
A recent study conducted by Sheba experts on the treatment of severe kaposiform lymphangiomatosis positive for NRAS mutation with MEK inhibitors (Trametinib) has shown promising results.

The lymphatic system, part of the immune system, is made up of vessels that help to protect the body from infection and foreign substances. It produces and releases lymphocytes (white blood cells) and other immune cells that monitor and then destroys pathogens — such as bacteria, viruses, parasites, and fungi — whenever they enter your body.

Symptoms of KLA usually start during childhood and include shortness of breath and coughing due to the accumulation of fluid around the lungs and heart. Other common symptoms include chest and body pain, abnormal bleeding and bruising, and soft masses under the skin. KLA is diagnosed based on such symptoms, laboratory testing, and a biopsy of the tumor tissue. The cause of this condition is unknown, and it is not thought to be hereditary.

Over the past few years, an activating NRAS mutation was found in the majority of KLA patients. The NRAS gene encodes the N-Ras protein, which is involved primarily in regulating cell division. 

A MEK inhibitor is a chemical or drug that blocks proteins called MEK1 and MEK2, which help control cell growth and survival. Recent studies indicated promising treatment results with the MEK inhibitor Trametinib in patients with complex lymphatic anomalies, including the typical NRAS mutation. 

Recently, Sheba experts presented the first description of successful Trametinib treatment on a 9-year-old child suffering from KLA and harboring the most characteristic NRAS p.Q61R mutation. Following the administration of a pediatric Trametinib dose, the patient continued follow-ups by a multidisciplinary team and extensive testing.

The young patient has been treated at Sheba for most of his life, with a consistently poor prognosis. Unfortunately, the boy was not qualified for a lung transplant, given his significant systemic illness. However, shortly after starting treatment with Trametinib, he reported increased appetite, reduced nausea, and overall improved well-being. 

After only two months of treatment, the boy gained 10% of his body weight, and his pulmonary function tests improved significantly, with chest CT imaging showing a marked improvement, as well as other positive indications. Fortunately, the Trametinib therapy was well tolerated with mild dermatological adverse effects. 

After years of treatment, these encouraging results have been a game changer in the young patient’s life. Consequently, the results indicate that this treatment can substantially change the prognosis of many patients with NRAS-associated lymphatic anomalies. Sheba is committed to continue leading innovative clinical research with the aim of providing patients with the most advanced treatments available. 

Elisheva Fisher: Nurturing Hope and Strength at Sheba’s Safra Children’s Hospital
Elisheva navigates her responsibilities with a profound sense of purpose, creating an environment where medical care is interwoven with emotional support. Her presence is a…
Read More
An Inspirational Model for Pediatric Psychiatric Care in Israel and Beyond
In an era where mental health has earned critical attention, finding compassionate and effective treatment for pediatric psychiatric concerns has become an objective for many…
Read More
Sheba’s Subterranean Refuge: Protecting the Pediatric ICU 
In the face of adversity, Sheba emerges as an epitome of resilience, responding to the relentless rocket attacks and ensuring the safety of young patients…
Read More